Iconic Therapeutics Lands $10,000,000 Series C Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=dfc81ac7-0f0b-40b0-8404-972274eb8d52 - Date
8/10/2016 - Company Name
Iconic Therapeutics - Mailing Address
395 Oyster Point Boulevard South San Francisco, CA 94080 USA - Company Description
Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. - Website
http://www.iconictherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$10,000,000 - Transaction Round
Series C - Proceeds Purposes
Proceeds from the financing will be used to advance development of Iconic’s lead molecule ICON-1 in retinal diseases as well begin clinical trials in ocular melanoma, Iconic’s first oncology indication. - M&A Terms
- Venture Investor
Xeraya Capital - Venture Investor
MPM Capital - Venture Investor
HBM BioCapital - Venture Investor
H.I.G. Capital - Venture Investor
Lundbeckfond Ventures - Venture Investor
Cormorant Asset Management - Venture Investor
Osage Partners
